Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

CD4 receptor diversity in chimpanzees protects against SIV infection.

Bibollet-Ruche F, Russell RM, Liu W, Stewart-Jones GBE, Sherrill-Mix S, Li Y, Learn GH, Smith AG, Gondim MVP, Plenderleith LJ, Decker JM, Easlick JL, Wetzel KS, Collman RG, Ding S, Finzi A, Ayouba A, Peeters M, Leendertz FH, van Schijndel J, Goedmakers A, Ton E, Boesch C, Kuehl H, Arandjelovic M, Dieguez P, Murai M, Colin C, Koops K, Speede S, Gonder MK, Muller MN, Sanz CM, Morgan DB, Atencia R, Cox D, Piel AK, Stewart FA, Ndjango JN, Mjungu D, Lonsdorf EV, Pusey AE, Kwong PD, Sharp PM, Shaw GM, Hahn BH.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3229-3238. doi: 10.1073/pnas.1821197116. Epub 2019 Feb 4.

2.

CHIIMP: An automated high-throughput microsatellite genotyping platform reveals greater allelic diversity in wild chimpanzees.

Barbian HJ, Connell AJ, Avitto AN, Russell RM, Smith AG, Gundlapally MS, Shazad AL, Li Y, Bibollet-Ruche F, Wroblewski EE, Mjungu D, Lonsdorf EV, Stewart FA, Piel AK, Pusey AE, Sharp PM, Hahn BH.

Ecol Evol. 2018 Jul 16;8(16):7946-7963. doi: 10.1002/ece3.4302. eCollection 2018 Aug.

3.

Reply to Forni et al., "Multiple Selected Changes May Modulate the Molecular Interaction between Laverania RH5 and Primate Basigin".

Plenderleith LJ, Liu W, MacLean OA, Li Y, Loy DE, Sundararaman SA, Bibollet-Ruche F, Learn GH, Hahn BH, Sharp PM.

MBio. 2018 May 22;9(3). pii: e00917-18. doi: 10.1128/mBio.00917-18. No abstract available.

4.

Loss of CXCR6 coreceptor usage characterizes pathogenic lentiviruses.

Wetzel KS, Yi Y, Yadav A, Bauer AM, Bello EA, Romero DC, Bibollet-Ruche F, Hahn BH, Paiardini M, Silvestri G, Peeters M, Collman RG.

PLoS Pathog. 2018 Apr 16;14(4):e1007003. doi: 10.1371/journal.ppat.1007003. eCollection 2018 Apr.

5.

Adaptive Evolution of RH5 in Ape Plasmodium species of the Laverania Subgenus.

Plenderleith LJ, Liu W, MacLean OA, Li Y, Loy DE, Sundararaman SA, Bibollet-Ruche F, Learn GH, Hahn BH, Sharp PM.

MBio. 2018 Jan 23;9(1). pii: e02237-17. doi: 10.1128/mBio.02237-17.

6.

Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee.

Barbian HJ, Jackson-Jewett R, Brown CS, Bibollet-Ruche F, Learn GH, Decker T, Kreider EF, Li Y, Denny TN, Sharp PM, Shaw GM, Lifson J, Acosta EP, Saag MS, Bar KJ, Hahn BH.

Retrovirology. 2017 Jun 2;14(1):35. doi: 10.1186/s12977-017-0359-0.

7.

BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH, Kaufmann DE, Smith AB 3rd, Sodroski J, Sauter D, Kirchhoff F, Gee K, Neil SJ, Evans DT, Finzi A.

J Virol. 2017 May 12;91(11). pii: e00219-17. doi: 10.1128/JVI.00219-17. Print 2017 Jun 1.

8.

Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn GH, Stürzel CM, Leoz M, Plantier JC, Geyer M, Hahn BH, Kirchhoff F.

J Virol. 2017 Feb 28;91(6). pii: e02177-16. doi: 10.1128/JVI.02177-16. Print 2017 Mar 15.

9.

Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.

Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, Learn GH, Plenderleith L, Smith AG, Barbian HJ, Russell RM, Gondim MV, Bahari CY, Shaw CM, Li Y, Decker T, Haynes BF, Shaw GM, Sharp PM, Borrow P, Hahn BH.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E590-E599. doi: 10.1073/pnas.1620144114. Epub 2017 Jan 9.

10.

The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.

Cadena C, Stavrou S, Manzoni T, Iyer SS, Bibollet-Ruche F, Zhang W, Hahn BH, Browne EP, Ross SR.

Retrovirology. 2016 Jun 30;13(1):45. doi: 10.1186/s12977-016-0280-y.

11.

The Role of the Antiviral APOBEC3 Gene Family in Protecting Chimpanzees against Lentiviruses from Monkeys.

Etienne L, Bibollet-Ruche F, Sudmant PH, Wu LI, Hahn BH, Emerman M.

PLoS Pathog. 2015 Sep 22;11(9):e1005149. doi: 10.1371/journal.ppat.1005149. eCollection 2015 Sep.

12.

Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.

Barbian HJ, Decker JM, Bibollet-Ruche F, Galimidi RP, West AP Jr, Learn GH, Parrish NF, Iyer SS, Li Y, Pace CS, Song R, Huang Y, Denny TN, Mouquet H, Martin L, Acharya P, Zhang B, Kwong PD, Mascola JR, Verrips CT, Strokappe NM, Rutten L, McCoy LE, Weiss RA, Brown CS, Jackson R, Silvestri G, Connors M, Burton DR, Shaw GM, Nussenzweig MC, Bjorkman PJ, Ho DD, Farzan M, Hahn BH.

MBio. 2015 Apr 21;6(2). pii: e00296-15. doi: 10.1128/mBio.00296-15.

13.

Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin.

Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, Bibollet-Ruche F, Plenderleith LJ, Peeters M, Geyer M, Sharp PM, Fackler OT, Hahn BH, Kirchhoff F.

Cell Host Microbe. 2014 Nov 12;16(5):639-50. doi: 10.1016/j.chom.2014.10.002. Epub 2014 Nov 12.

14.

African origin of the malaria parasite Plasmodium vivax.

Liu W, Li Y, Shaw KS, Learn GH, Plenderleith LJ, Malenke JA, Sundararaman SA, Ramirez MA, Crystal PA, Smith AG, Bibollet-Ruche F, Ayouba A, Locatelli S, Esteban A, Mouacha F, Guichet E, Butel C, Ahuka-Mundeke S, Inogwabini BI, Ndjango JB, Speede S, Sanz CM, Morgan DB, Gonder MK, Kranzusch PJ, Walsh PD, Georgiev AV, Muller MN, Piel AK, Stewart FA, Wilson ML, Pusey AE, Cui L, Wang Z, Färnert A, Sutherland CJ, Nolder D, Hart JA, Hart TB, Bertolani P, Gillis A, LeBreton M, Tafon B, Kiyang J, Djoko CF, Schneider BS, Wolfe ND, Mpoudi-Ngole E, Delaporte E, Carter R, Culleton RL, Shaw GM, Rayner JC, Peeters M, Hahn BH, Sharp PM.

Nat Commun. 2014;5:3346. doi: 10.1038/ncomms4346.

15.

Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G.

Letko M, Silvestri G, Hahn BH, Bibollet-Ruche F, Gokcumen O, Simon V, Ooms M.

J Virol. 2013 Nov;87(21):11861-71. doi: 10.1128/JVI.01944-13. Epub 2013 Aug 28.

16.

The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.

Kluge SF, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, Hahn BH, Kirchhoff F.

Retrovirology. 2013 Mar 20;10:32. doi: 10.1186/1742-4690-10-32.

17.

Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein.

Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, Learn GH, Bibollet-Ruche F, Fritz JV, Fackler OT, Hahn BH, Kirchhoff F.

PLoS Pathog. 2012 Dec;8(12):e1003093. doi: 10.1371/journal.ppat.1003093. Epub 2012 Dec 20.

18.

Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host.

Götz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigele A, Geyer M, Bibollet-Ruche F, Learn GH, Fackler OT, Hahn BH, Kirchhoff F.

Cell Host Microbe. 2012 Sep 13;12(3):373-80. doi: 10.1016/j.chom.2012.07.008.

19.

Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.

Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JP, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Nov;86(22):12115-28. doi: 10.1128/JVI.01632-12. Epub 2012 Aug 29.

20.

Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir.

Li Y, Ndjango JB, Learn GH, Ramirez MA, Keele BF, Bibollet-Ruche F, Liu W, Easlick JL, Decker JM, Rudicell RS, Inogwabini BI, Ahuka-Mundeke S, Leendertz FH, Reynolds V, Muller MN, Chancellor RL, Rundus AS, Simmons N, Worobey M, Shaw GM, Peeters M, Sharp PM, Hahn BH.

J Virol. 2012 Oct;86(19):10776-91. doi: 10.1128/JVI.01498-12. Epub 2012 Jul 25.

21.

Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation.

Bibollet-Ruche F, Heigele A, Keele BF, Easlick JL, Decker JM, Takehisa J, Learn G, Sharp PM, Hahn BH, Kirchhoff F.

J Clin Invest. 2012 May;122(5):1644-52. doi: 10.1172/JCI61429. Epub 2012 Apr 16.

22.

Budding of retroviruses utilizing divergent L domains requires nucleocapsid.

Bello NF, Dussupt V, Sette P, Rudd V, Nagashima K, Bibollet-Ruche F, Chen C, Montelaro RC, Hahn BH, Bouamr F.

J Virol. 2012 Apr;86(8):4182-93. doi: 10.1128/JVI.07105-11. Epub 2012 Feb 15.

23.

Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

de Silva TI, Aasa-Chapman M, Cotten M, Hué S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R.

J Virol. 2012 Jan;86(2):930-46. doi: 10.1128/JVI.06126-11. Epub 2011 Nov 9.

24.

Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Jan;86(2):947-60. doi: 10.1128/JVI.06155-11. Epub 2011 Oct 26.

25.

The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses.

Schmökel J, Sauter D, Schindler M, Leendertz FH, Bailes E, Dazza MC, Saragosti S, Bibollet-Ruche F, Peeters M, Hahn BH, Kirchhoff F.

J Virol. 2011 Jan;85(2):742-52. doi: 10.1128/JVI.02087-10. Epub 2010 Nov 10.

26.

4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.

Nakamura KJ, Gach JS, Jones L, Semrau K, Walter J, Bibollet-Ruche F, Decker JM, Heath L, Decker WD, Sinkala M, Kankasa C, Thea D, Mullins J, Kuhn L, Zwick MB, Aldrovandi GM.

PLoS One. 2010 Mar 23;5(3):e9786. doi: 10.1371/journal.pone.0009786.

27.

Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F.

Cell Host Microbe. 2009 Nov 19;6(5):409-21. doi: 10.1016/j.chom.2009.10.004.

28.

Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.

Decker JM, Zammit KP, Easlick JL, Santiago ML, Bonenberger D, Hahn BH, Kutsch O, Bibollet-Ruche F.

Virology. 2009 Nov 10;394(1):109-18. doi: 10.1016/j.virol.2009.08.027. Epub 2009 Sep 12.

29.

Determinants of the establishment of human immunodeficiency virus type 1 latency.

Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O.

J Virol. 2009 Apr;83(7):3078-93. doi: 10.1128/JVI.02058-08. Epub 2009 Jan 14.

30.

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM.

J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19.

31.

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.

32.
33.

Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees.

Liu W, Worobey M, Li Y, Keele BF, Bibollet-Ruche F, Guo Y, Goepfert PA, Santiago ML, Ndjango JB, Neel C, Clifford SL, Sanz C, Kamenya S, Wilson ML, Pusey AE, Gross-Camp N, Boesch C, Smith V, Zamma K, Huffman MA, Mitani JC, Watts DP, Peeters M, Shaw GM, Switzer WM, Sharp PM, Hahn BH.

PLoS Pathog. 2008 Jul 4;4(7):e1000097. doi: 10.1371/journal.ppat.1000097.

34.

Primate lentivirus capsid sensitivity to TRIM5 proteins.

Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou T.

J Virol. 2008 Jul;82(13):6772-7. doi: 10.1128/JVI.00410-08. Epub 2008 Apr 16.

35.

4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM, Morris L.

J Virol. 2008 Mar;82(5):2367-75. Epub 2007 Dec 19.

36.

Adaptation of HIV-1 to its human host.

Wain LV, Bailes E, Bibollet-Ruche F, Decker JM, Keele BF, Van Heuverswyn F, Li Y, Takehisa J, Ngole EM, Shaw GM, Peeters M, Hahn BH, Sharp PM.

Mol Biol Evol. 2007 Aug;24(8):1853-60. Epub 2007 Jun 1.

37.

Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees.

Takehisa J, Kraus MH, Decker JM, Li Y, Keele BF, Bibollet-Ruche F, Zammit KP, Weng Z, Santiago ML, Kamenya S, Wilson ML, Pusey AE, Bailes E, Sharp PM, Shaw GM, Hahn BH.

J Virol. 2007 Jul;81(14):7463-75. Epub 2007 May 9.

38.

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L; CAPRISA 002 Study Team.

J Virol. 2007 Jun;81(12):6187-96. Epub 2007 Apr 4.

39.

Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, Derdeyn CA.

J Virol. 2007 Jun;81(11):5658-68. Epub 2007 Mar 14.

40.

Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Mestecky J, Gao F, Haynes BF, Shaw GM, Muldoon M, Korber BT, Hahn BH.

Virology. 2007 Mar 30;360(1):218-34. Epub 2006 Nov 13.

41.

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA.

J Virol. 2007 Feb;81(3):1350-9. Epub 2006 Nov 1. Erratum in: J Virol. 2007 Nov;81(22):12715.

42.

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Haynes BF, Shaw GM, Korber BT, Hahn BH.

Virology. 2006 Sep 1;352(2):438-49. Epub 2006 Jun 14.

43.

Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.

Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F.

Cell. 2006 Jun 16;125(6):1055-67.

44.

Chimpanzee reservoirs of pandemic and nonpandemic HIV-1.

Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH.

Science. 2006 Jul 28;313(5786):523-6. Epub 2006 May 25.

45.

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA.

J Virol. 2006 Jun;80(11):5211-8. Erratum in: J Virol. 2007 Nov;81(22):12716.

46.

Widely varying SIV prevalence rates in naturally infected primate species from Cameroon.

Aghokeng AF, Liu W, Bibollet-Ruche F, Loul S, Mpoudi-Ngole E, Laurent C, Mwenda JM, Langat DK, Chege GK, McClure HM, Delaporte E, Shaw GM, Hahn BH, Peeters M.

Virology. 2006 Feb 5;345(1):174-89. Epub 2005 Oct 27.

47.

Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2.

Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, Fruteau C, Noë R, Peeters M, Brookfield JF, Shaw GM, Sharp PM, Hahn BH.

J Virol. 2005 Oct;79(19):12515-27. Erratum in: J Virol. 2006 May;80(9):4645.

48.

Antigenic conservation and immunogenicity of the HIV coreceptor binding site.

Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Exp Med. 2005 May 2;201(9):1407-19.

49.

Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2).

Bibollet-Ruche F, Gao F, Bailes E, Saragosti S, Delaporte E, Peeters M, Shaw GM, Hahn BH, Sharp PM.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1377-81.

50.

Further investigation of simian immunodeficiency virus Vif function in human cells.

Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH.

J Virol. 2004 Nov;78(21):12041-6.

Supplemental Content

Loading ...
Support Center